Supplementary Figure S8 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas
Abstract
Figure S8. The brigatinib+INK128 combination, but not the monotherapies, markedly downregulated several YAP target genes in treated AG-NF2-Men cells.
Fields of Study & Subjects
Meningioma and schwannoma management
Hippo pathway signaling and YAP/TAZ
Neurofibromatosis and Schwannoma Cases
Publication details
- Publication date
- 27 January 2026